RxDoctor Payments DataLook up a doctor →

Eng Keong Tan, MD

Endocrinology, Diabetes & Metabolism · Carson City, NVNPI 1811339013

Payments from drug & device makers

$12,147in general payments, 2019–2025

Across 403 payments — averaging $30.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Medtronic$1K
  • Lilly USA, LLC$1K
  • Mannkind Corporation$788
  • Boehringer Ingelheim$745
  • Insulet Corporation$729
  • plus $6K from 38 others
$156in research payments, 2019–2025

Across 1 payment — averaging $156.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Corcept Therapeutics$156

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)49$1,785
Medtronic(2 entities)38$1,345
Lilly USA, LLC49$1,079
Mannkind Corporation36$788
Boehringer Ingelheim27$745
Insulet Corporation26$729
Novo Nordisk23$631
Sanofi-aventis U.S. LLC12$412
Radius Health, Inc.12$409
Ascendis Pharma Endocrinology Inc7$404
AstraZeneca(2 entities)11$390
Abbott21$384
Tandem Diabetes Care, Inc.11$382
Bayer8$320
Xeris Pharmaceuticals, Inc.11$313
Recordati_rare_diseases_inc.7$247
Corcept Therapeutics6$210
Kyowa Kirin, Inc.6$151
Chiesi USA, Inc.1$148
Dexcom, Inc.6$135
Amryt Pharma Holdings Ltd1$129
Soleno Therapeutics, Inc.1$119
AbbVie4$102
Ascensia Diabetes Care US Inc.2$94
Biomarin Pharmaceutical Inc.1$88
Lexicon Pharmaceuticals, Inc.1$83
Johnson & Johnson1$72
IBSA Pharma Inc.3$52
Zealand Pharma US, Inc.2$46
Ultragenyx Pharmaceutical Inc.3$44
Companion Medical, Inc.2$42
Sequel Med Tech, LLC2$32
Vistapharm, Inc.2$28
EUSA Pharma (US) LLC1$27
Antares Pharma, Inc.1$24
RGH Enterprises LLC1$22
Halozyme Inc1$22
Almatica Pharma LLC1$21
GRT US Holding, Inc.1$19
Merck1$18
Amarin Pharma, Inc.1$16
Shire North American Group Inc1$15
Otsuka America Pharmaceutical, Inc.1$13
Regeneron Healthcare Solutions, Inc.1$11

How this compares

$12,147 in reported general payments places this provider in the 70th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.

See all endocrinology, diabetes & metabolism providers in Nevada →

Medicare billing

Part B allowed, 2024
$177,635
Medicare patients
531
Services billed
2,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Carson City

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →